{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:43:20Z","timestamp":1792197800277,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Fetal and Neonatal Medicine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.siny.2012.10.003","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T22:01:16Z","timestamp":1352152876000},"page":"28-34","source":"Crossref","is-referenced-by-count":64,"title":["Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration"],"prefix":"10.1016","volume":"18","author":[{"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.siny.2012.10.003_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.siny.2004.11.003","article-title":"The use of unlicensed and off-label medicines in the neonate","volume":"10","author":"Conroy","year":"2005","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.siny.2012.10.003_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00431-005-1698-8","article-title":"A\u00a0literature review on off-label drug use in children","volume":"164","author":"Pandolfini","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.siny.2012.10.003_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00005237-200209000-00006","article-title":"Vancomycin and gentamicin in neonates: hindsight, current controversies, and forethought","volume":"16","author":"Dawson","year":"2002","journal-title":"J\u00a0Perinat Neonatal Nurs"},{"key":"10.1016\/j.siny.2012.10.003_bib4","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1542\/peds.110.4.e42","article-title":"Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices","volume":"110","author":"Rubin","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.siny.2012.10.003_bib5","series-title":"Revised priority list for studies into off-patent paediatric medicinal products (EMA\/98717\/2012)","author":"European Medicines Agency","year":"2009"},{"key":"10.1016\/j.siny.2012.10.003_bib6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/INF.0b013e3181acf6bd","article-title":"Early and late onset sepsis in late preterm infants","volume":"28","author":"Cohen-Wolkowiez","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.siny.2012.10.003_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.pcl.2009.04.003","article-title":"Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis","volume":"56","author":"Koenig","year":"2009","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.siny.2012.10.003_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/AOG.0b013e31824532f6","article-title":"Intrapartum evidence of early-onset group B streptococcus","volume":"119","author":"Tudela","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.siny.2012.10.003_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(96)70191-9","article-title":"Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network","volume":"129","author":"Stoll","year":"1996","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.siny.2012.10.003_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJMoa012657","article-title":"Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants","volume":"347","author":"Stoll","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.siny.2012.10.003_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.earlhumdev.2010.01.012","article-title":"Risk factors and prevention of late onset sepsis in premature infants","volume":"86","author":"Downey","year":"2010","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.siny.2012.10.003_bib12","doi-asserted-by":"crossref","first-page":"e1000213","DOI":"10.1371\/journal.pmed.1000213","article-title":"New approaches to preventing, diagnosing, and treating neonatal sepsis","volume":"7","author":"Edmond","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.siny.2012.10.003_bib13","first-page":"CD004501","article-title":"Antibiotic regimens for suspected late onset sepsis in newborn infants","volume":"3","author":"Gordon","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.siny.2012.10.003_bib14","first-page":"CD004495","article-title":"Antibiotic regimens for suspected early neonatal sepsis","volume":"4","author":"Mtitimila","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.siny.2012.10.003_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.siny.2012.10.003_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/AAC.37.5.1132","article-title":"Serum protein-binding characteristics of vancomycin","volume":"37","author":"Sun","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.idc.2004.04.014","article-title":"Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin","volume":"18","author":"Lundstrom","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.siny.2012.10.003_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.34.5.792","article-title":"Vancomycin pharmacokinetics in burn patients and intravenous drug abusers","volume":"34","author":"Rybak","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/clpt.1988.74","article-title":"Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects","volume":"43","author":"Golper","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.siny.2012.10.003_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003088-200443070-00001","article-title":"Vancomycin: pharmacokinetics and administration regimens in neonates","volume":"43","author":"de Hoog","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.siny.2012.10.003_bib21","unstructured":"Baxter Healthcare Corp. Label information. Vancomycin hydrochloride injection solution. Deerfield, IL: Baxter Healthcare Corp. www.medlibrary.com; February 2012."},{"key":"10.1016\/j.siny.2012.10.003_bib22","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib23","first-page":"1863","article-title":"Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study","volume":"53","author":"Wysocki","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib24","first-page":"2460","article-title":"Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients","volume":"45","author":"Pea","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/adc.2007.128280","article-title":"Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented gram-positive infections: a new dosage schedule","volume":"93","author":"Plan","year":"2008","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.siny.2012.10.003_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2125.1998.00763.x","article-title":"Constant rate infusion of vancomycin in premature neonates: a new dosage schedule","volume":"46","author":"Pawlotsky","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.siny.2012.10.003_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/adc.2010.196402","article-title":"Vancomycin prescription in neonates and young infants: toward a simplified dosage","volume":"96","author":"Oudin","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.siny.2012.10.003_bib29","series-title":"Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority","author":"World Health Organization","year":"1999"},{"key":"10.1016\/j.siny.2012.10.003_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/FTD.0b013e318243e739","article-title":"In\u00a0vivo inferiority of generic product compared with branded vancomycin: a paradigm shift","volume":"34","author":"Jong","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.siny.2012.10.003_bib31","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.01044-09","article-title":"Generic vancomycin products fail in\u00a0vivo despite being pharmaceutical equivalents of the innovator","volume":"54","author":"Vesga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/AAC.05129-11","article-title":"Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model","volume":"56","author":"Rodriguez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib33","doi-asserted-by":"crossref","first-page":"e10744","DOI":"10.1371\/journal.pone.0010744","article-title":"Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model","volume":"5","author":"Zuluaga","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.siny.2012.10.003_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2334-10-153","article-title":"In\u00a0vitro and in\u00a0vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin","volume":"10","author":"Rodriguez","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.siny.2012.10.003_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00228-010-0974-3","article-title":"Modelling and simulation as research tools in paediatric drug development","volume":"67","author":"Bellanti","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.siny.2012.10.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin: a review of population pharmacokinetic analyses","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.siny.2012.10.003_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.siny.2012.10.003_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/FTD.0b013e31806db3f5","article-title":"Renal drug clearance in preterm neonates: relation to prenatal growth","volume":"29","author":"Allegaert","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.siny.2012.10.003_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.48.4.1159-1167.2004","article-title":"Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates","volume":"48","author":"Kimura","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib40","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01370-09","article-title":"Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination","volume":"54","author":"Lo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.siny.2012.10.003_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2125.2010.03736.x","article-title":"Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline","volume":"70","author":"Marqu\u00e9s-Mi\u00f1ana","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.siny.2012.10.003_bib42","doi-asserted-by":"crossref","first-page":"F221","DOI":"10.1136\/fn.81.3.F221","article-title":"Pharmacokinetics and dose requirements of vancomycin in neonates","volume":"81","author":"Grimsley","year":"1999","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.siny.2012.10.003_bib43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/00912700122010898","article-title":"The influences of renal function and maturation on vancomycin elimination in newborns and infants","volume":"41","author":"Capparelli","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.siny.2012.10.003_bib44","unstructured":"Zhao W, Kaguelidou F, Biran V, et\u00a0al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol [Epub ahead of print]. http:\/\/dx.doi.org.10.1111\/j.1365-2125.2012.04406.x."},{"key":"10.1016\/j.siny.2012.10.003_bib45","unstructured":"United States Food and Drug Administration. Guidance for industry: exposure\u2013response relationships \u2014 study design, data analysis, and regulatory applications. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072109.pdf."},{"key":"10.1016\/j.siny.2012.10.003_bib46","unstructured":"European Medicines Agency. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (Doc. Ref.\u00a0CPMP\/EWP\/2655\/99). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientificguideline\/2009\/09\/WC500003420.pdf."},{"key":"10.1016\/j.siny.2012.10.003_bib47","unstructured":"European Medicines Agency. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP\/EWP\/558\/95 rev\u00a01). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf."},{"key":"10.1016\/j.siny.2012.10.003_bib48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.siny.2012.10.003_bib49","first-page":"140","article-title":"Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong","volume":"60","author":"Ho","year":"2010","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.siny.2012.10.003_bib50","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/518451","article-title":"Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus","volume":"44","author":"Mohr","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.siny.2012.10.003_bib51","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2010.03.005","article-title":"Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation","volume":"32","author":"Frymoyer","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.siny.2012.10.003_bib52","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","article-title":"Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","author":"Rybak","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.siny.2012.10.003_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003088-199733010-00004","article-title":"Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children","volume":"33","author":"Rodvold","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.siny.2012.10.003_bib54","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.siny.2012.10.003_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/BF03259891","article-title":"Vancomycin ototoxicity and nephrotoxicity. A review","volume":"3","author":"Bailie","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"10.1016\/j.siny.2012.10.003_bib56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"McKamy","year":"2011","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.siny.2012.10.003_bib57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0022-3476(84)80036-0","article-title":"Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children","volume":"105","author":"Odio","year":"1984","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.siny.2012.10.003_bib58","first-page":"278","article-title":"Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children","volume":"8","author":"Goren","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.siny.2012.10.003_bib59","first-page":"27","article-title":"Safety of vancomycin with or without gentamicin in neonates","volume":"12","author":"Linder","year":"1993","journal-title":"Neonatal Network"},{"key":"10.1016\/j.siny.2012.10.003_bib60","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1093\/clinids\/3.Supplement.S282","article-title":"Pharmacology and efficacy of vancomycin for staphylococcal infections in children","volume":"3","author":"Schaad","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.siny.2012.10.003_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/15563659209038639","article-title":"Exchange transfusion and multidose activated charcoal following vancomycin overdose","volume":"30","author":"Burkhart","year":"1992","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.siny.2012.10.003_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mpd.2003.mpd037","article-title":"Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss","volume":"142","author":"de Hoog","year":"2003","journal-title":"J\u00a0Pediatr"}],"container-title":["Seminars in Fetal and Neonatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744165X12001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744165X12001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T13:55:12Z","timestamp":1540130112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1744165X12001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1744165X12001102"],"URL":"https:\/\/doi.org\/10.1016\/j.siny.2012.10.003","relation":{},"ISSN":["1744-165X"],"issn-type":[{"value":"1744-165X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}